Navigation Links
Study finds genomic differences in types of cervical cancer
Date:8/23/2013

BOSTON A new study has revealed marked differences in the genomic terrain of the two most common types of cervical cancer, suggesting that patients might benefit from therapies geared to each type's molecular idiosyncrasies.

The study, published August 23, 2013 in the online version of the journal Cancer by researchers at Dana-Farber Cancer Institute and Brigham and Women's Hospital (BWH), is the first to compare the spectrum of cancer-related gene mutations in the two main subtypes of cervical cancer adenocarcinoma and squamous cell carcinoma. In tests on 80 cervical tumor samples, the investigators found high rates of mutations in two genes: PIK3CA and KRAS. While PIK3CA mutations appeared in both subtypes, KRAS mutations were found only in adenocarcinomas.

By linking their findings to data on patients' treatment and survival, researchers found that PIK3CA mutations are associated with a shorter survival period: patients whose tumors carried these mutations lived a median of 67 months after diagnosis compared with 90 months for patients whose tumors lacked the mutations.

"We have historically treated cervical cancers as one disease," says the study's lead author, Alexi Wright, MD, MPH, of the Susan F. Smith Center for Women's Cancers at Dana-Farber. "However, our findings suggest that some patients may be at higher risk of dying from their disease and might benefit from a more tailored treatment approach."

The discovery of high rates of PIK3CA mutations in the cervical tumor samples suggests that many patients could benefit from drugs known as PI3-kinase inhibitors, which target the family of proteins associated with the gene, the authors say. Patients with the adenocarcinoma subtype of cervical cancer may benefit from targeted agents known as MEK inhibitors, which have shown some success in clinical trials.

Cervical cancer is the second leading cause of cancer deaths among women worldwide, responsible for 275,000 deaths annually. While Pap tests have helped decrease the incidence of squamous cell cervical cancer, adenocarcinomas now account for nearly a quarter of all cervical cancers, up from 5 percent 20 years ago.

In the study, investigators probed the DNA of 80 cervical cancer tumors 40 adenocarcinomas and 40 squamous cell carcinomas for 1,200 mutations in hundreds of genes linked to cancer. The probe was done with OncoMap, a system developed at Dana-Farber to test large numbers of tumor samples for cancer-related genes. They found that 31 percent of the samples had PIK3CA mutations; 17.5 percent of the adenocarcinomas (and none of the squamous cell carcinomas) had KRAS mutations; and 7.5 percent of the squamous cell carcinomas (but none of the adenocarcinomas) had a rare mutation in the gene EGFR.

"While current treatment strategies don't take into account whether cervical tumors are adenocarcinomas or squamous cell carcinomas, our study suggests that identifying and targeting distinct subsets of patients may improve outcomes for women with early or late-stage disease," Wright comments.


'/>"/>

Contact: Robbin Ray
robbin_ray@dfci.harvard.edu
617-632-4090
Dana-Farber Cancer Institute
Source:Eurekalert

Related medicine news :

1. LSUHSC study reports racial/ethnic differences in young people with cancer
2. 246 Study Participants Reported the Health Benefits of the TA-65 Telomerase Activator
3. Single injection may revolutionize melanoma treatment, Moffitt study shows
4. Study helps explain increased melanoma risk in individuals with red hair
5. UCLA Nursing study suggests focus on lifestyle changes -- not weight loss -- is key to kids health
6. Study finds grandmothers who raise their grandkids struggle with depression
7. Study: Disease caused by repeat brain trauma in athletes may affect memory, mood, behavior
8. Case study collection diagnostic dilemmas hones physicians skills
9. Shocking New CDC Study Confirms U.S. Tick-Borne Disease Epidemic, Shows Lyme Disease Rates 10X Higher than Previously Reported
10. Penn Medicine study shows survivorship care plans empower cancer patients
11. UCLA study suggests iron is at core of Alzheimers disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... ... January 20, 2017 , ... “I Forgive You”: a fine examination of how God handles ... the creation of published author, Stephen Miller, who, for over ten long years has been ... him. Born in Trinidad and Tobago, he has been serving the Lord for over twenty ...
(Date:1/20/2017)... ... ... “Journey to Christmas:” a beautiful and enchanting tale that teaches children the true meaning of ... three in Oklahoma City, and a devoted woman of faith. , “Becoming a parent ... the back of my mind for years, but actually doing it might have been a ...
(Date:1/20/2017)... ... January 20, 2017 , ... “God's Miracle Man: Against All Odds”: ... the creation of published author, Keith C. A. Tucker, son of Minister Delores Pinnock ... Outreach pastured by Reverend Mark Hardy , “While sitting up in bed, I felt ...
(Date:1/19/2017)... Los Angeles (PRWEB) , ... January 19, 2017 , ... ... Care Act will be repealed by Congressional political games that circumvent health needs of ... First Stand Rally” capture the human anxieties and needs government public servants were suppose ...
(Date:1/19/2017)... , ... January 19, 2017 , ... This month, the ... that the name of their drug rehab center in Delray Beach, Florida has been ... that not only stars such as Philip Seymour Hoffman and Chris Farley are dying ...
Breaking Medicine News(10 mins):
(Date:1/20/2017)... Jan 20, 2017 Research and Markets ... Market (by Devices, Implant Types, OTC Amplifiers, Diagnostic Instruments), Sales ... their offering. ... Global Hearing Aids Market Sales Volume, Company Analysis and ... high-growth hearing aid industry. The growing prevalence of ...
(Date:1/20/2017)... -- Stock-Callers.com today evaluates the following Drug Manufacturers ... Nordisk A/S (NYSE: NVO ), Sucampo Pharmaceuticals Inc. ... (NASDAQ: PTX ). These stocks belong to the ... 2017, finishing near its session lows. As per a NASDAQ ... shares of health care companies in the S&P 500 also ...
(Date:1/20/2017)... , Jan. 20, 2017  Palladian Health, a ... announced the launch of an opioid management program ... on opioids and helps stem the growing tide ... prescribed to treat chronic non-cancer pain (back pain, ... risks and lack of evidence regarding long-term effectiveness. ...
Breaking Medicine Technology: